FY25 consensus $3.01. Backs FY25 revenue view $61B-$64B, consensus $62.57B.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PFE:
- Pfizer’s Long-Term Study on Ritlecitinib Offers Hope for Alopecia Areata Treatment
- Pfizer’s Phase 1 Study on Drug Interactions: Key Insights for Investors
- Pfizer’s PF-07275315 Study: A Step Forward in Drug Development
- Pfizer’s Phase 1 Study on PF-07258669: Key Insights for Investors
- Pfizer’s Xeljanz Study: A New Chapter in Juvenile Arthritis Treatment